Astrotech Corp (ASTC) - Q1 2025 (Ended Sept 30, 2024) Summary
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2024 (Fiscal Q1 2025). Astrotech Corporation is a Delaware corporation developing and commercializing mass spectrometry (MS) technology through wholly-owned subsidiaries: 1st Detect (security), AgLAB (agriculture/cannabis), BreathTech (health), and Pro-Control (industrial). The company operates as a single reporting segment.
Key Financial Metrics
| Metric (in thousands) | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $34 | $425 |
| Gross Profit | $9 | $183 |
| Gross Margin | 26% | 43% |
| Operating Expenses | $3,637 | $3,518 |
| Net Loss | $(3,278) | $(2,912) |
| Loss Per Share (Basic/Diluted) | $(2.01) | $(1.79) |
| Cash and Cash Equivalents | $6,518 | $13,090 |
| Short-Term Investments | $21,790 | $21,474 |
| Total Liabilities | $2,388 | $2,833 |
| Working Capital | $29,485 | $32,200 |
Note: The filing text does not provide a specific long-term debt figure; total liabilities are primarily composed of lease obligations and accrued expenses.
Material Changes vs. Prior Period
- Revenue Decline: Revenue dropped 92% to $34,000 from $425,000. Management attributes this to the absence of device sales in Q1 2025, with revenue derived solely from consumables and maintenance services, whereas Q1 2024 included significant device sales.
- Margin Compression: Gross margin fell from 43% to 26% due to the shift in revenue mix from high-margin hardware sales to lower-margin services.
- Operating Expenses: Total operating expenses increased 3.4% to $3.6 million. R&D expenses rose 4.1% due to increased personnel for technology development, while SG&A increased 2.6% due to marketing activities.
- Cash Burn: Cash and cash equivalents decreased by $3.9 million during the quarter. Net cash used in operating activities was $3.7 million, an increase of $636,000 compared to the prior year quarter.
Outlook, Risks, and Management Commentary
- Product Progress: The TRACER 1000 (explosives detector) is deployed in 30 locations across 14 countries. It received TSA approval for the Air Cargo Security Technology List in June 2024 and is undergoing Stage II field trials. The AgLAB 1000-D2 is in field trials showing potential yield improvements of 20%+ for cannabis distillation.
- Liquidity: The company holds approximately $28.3 million in liquid assets (cash + short-term investments). Management states there have been no material updates to liquidity expectations since the 2024 Annual Report.
- Risks: Key risks include reliance on a single customer for 100% of Q1 2025 revenue, uncertainty in government funding and procurement, supply chain inflation, and the long timeline required for regulatory approval of new medical applications (BreathTech).
- Tax Position: The company maintains a full valuation allowance against net deferred tax assets, resulting in a 0% effective tax rate.
Investor Verification Checklist
- Customer Concentration: Verify the identity and stability of the single customer comprising 100% of Q1 2025 revenue.
- TSA Certification Timeline: Monitor the outcome of the TRACER 1000 Stage II field trials and the timeline for addition to the TSA "qualified" list.
- Cash Runway: Assess the burn rate against the $28.3 million liquid asset base to determine the need for future capital raises.
- AgLAB Commercialization: Track the conversion of AgLAB field trial results into signed commercial leases or sales contracts.
- Stock-Based Compensation: Note the $216,000 expense in Q1 and the remaining $1.5 million obligation over 2.32 years, which impacts future operating costs.